Managing Mild Cognitive Impairment in the Age of Anti-amyloid Therapies
Amy Abramowitz,Kim Johnson,Michael Weber,Tyler Deegan,Heidi Roth
DOI: https://doi.org/10.1016/j.jagp.2024.01.059
2024-04-01
Abstract:Since the approval of anti-amyloid therapies, there has been increased focus on recognizing early cognitive changes and treating patients in this stage. Early cognitive changes are not always recognized or diagnosed. When mild cognitive impairment (MCI) is diagnosed, there is not always a comprehensive assessment of comorbidities that contribute to cognitive problems such as sleep disorders, inappropriate medication use, and psychiatric disorders including depression, anxiety, substance abuse. Assessment of MCI should often include imaging, spinal fluid biomarkers, and genetic testing. Counseling should be done regarding the appropriateness, risks, and benefits of anti-amyloid therapy. In this session, we will discuss the development of the Aging Brain Clinic (ABC) at UNC where we manage patients with MCI. Our clinic was inspired by comprehensive care models, but our focus is on optimizing cognition in older adults with MCI by 1) providing interdisciplinary evaluation and treatment of cognitive disorders, 2) implementing interventions longitudinally within the clinical setting to focus on factors that worsen cognitive impairment particularly medication side effects, sleep disturbance, and anxiety/depression and 3) focusing on helping patients understand their diagnosis, risk of worsening cognition, promoting wellbeing, and adapt to cognitive changes in their everyday life. We will discuss our clinic structure include referral process, registry development, measures, personnel, and outcomes. We will share data from our ABC registry regarding cognition, depression, anxiety, sleep measures, and function from patients in our clinic. We will also discuss anti-amyloid mechanism of action, review approved therapies, and discuss best practices for prescribing and monitoring. The approval of anti-amyloid therapy has increased interest in early diagnosis of cognitive impairment, interventions for MCI, and ways of improving quality of life for people living with cognitive impairment. There is also a risk that focusing on medication treatment for MCI may compromise time spent on patient-centered, individualized assessment of cognitive impairment, psychoeducation, lifestyle change, and interventions targeting comorbidities of cognitive impairment. We will share how the ABC clinic has incorporated anti-amyloid therapy into our workflow and approach to managing patients with early cognitive impairment.
psychiatry,geriatrics & gerontology,gerontology